Table I. Age and sex distribution, and clinical findings in CWD IRIS patients and CWD non-IRIS patients (data of all 189 patients and data of the group of 57 patients included in the study with immunological data) before onset of treatment
Non-IRIS CWD (All 189 Patients)Non-IRIS CWD (57 Patients Included with Data)IRISp Value (IRIS to All 189)p Value (IRIS to 57)
Agea57 ± 12 y (95% CI: 55–59 y)57 ± 10 y (95% CI: 55–60 y)57 ± 10 y (95% CI: 53–62 y)0.9780.828
Sexa46 female, 143 male8 female, 49 male5 female, 19 male0.8050.513
C-reactive proteina33 ± 53 mg/l (95% CI: 21–44 mg/l)45 ± 69 mg/l (95% CI: 23–66 mg/l)32 ± 49 mg/l (95% CI: 7–58 mg/l)0.9560.573
Previous immunosuppressive treatmentb25/115 (21.7%) (95% CI: 13.5–29.9%)8/53 (15.1%) (95% CI: 7.5–22.7%)19/23 (82.6%) (95% CI: 67.1–98.1%)<0.0001<0.0001
Duration of immunosuppressive treatment51 ± 33 mo (range: 12–120 mo) (95% CI: 34–69 mo)60 ± 42 mo (range: 12–120 mo) (95% CI: 25–95 mo)69 ± 46 mo (range: 1–156 mo) (95% CI: 47–91 mo)0.2840.683
  • a For age, C-reactive protein, and duration of immunosuppressive treatment, the mean ± SD are given.

  • b In most of the cases, prednisolone, in some of them followed by methotrexate, cyclosporine, sulphasalazine, cyclophosphamide, and/or biologicals. (For details of previous treatment, see Supplemental Table I.)